The possibility of novel antiplatelet peptides: the physiological effects of low molecular weight HSPs on platelets

Curr Pharm Des. 2006;12(7):887-92. doi: 10.2174/138161206776056047.

Abstract

Some low molecular mass heat shock proteins (HSPs) appear to act as molecular chaperones, but their exact physiological roles have not been fully elucidated. We reported on a physiological role of HSP20, HSP27 and alphaB-crystallin on platelet function in vitro and ex vivo. HSP20 and alphaB-crystallin inhibited platelet aggregation using human platelets dose-dependently induced by thrombin or botrocetin. On the other hand, HSP27, the other type of low molecular mass HSP, did not affect platelet aggregation. When HSP20 or alphaB-crystallin was injected intravenously as a bolus in hamsters, the development of thrombus after endothelial injury was prevented. Moreover, 9 amino-acid sequences isolated from HSP20 or alphaB-crystallin significantly reduced platelet aggregation induced by TRAP, but not a PAR-4 agonist. These findings strongly suggest that HSP20 or alphaB-crystallin can act intercellularly to regulate platelet functions. Our results may provide the basis for a novel defensive system to thrombus formation in vivo.

Publication types

  • Review

MeSH terms

  • Animals
  • Blood Platelets / drug effects*
  • Blood Platelets / physiology
  • Heat-Shock Proteins, Small / pharmacology
  • Heat-Shock Proteins, Small / physiology*
  • Humans
  • Models, Biological
  • Peptides / chemistry
  • Peptides / pharmacology*
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / chemistry
  • Platelet Aggregation Inhibitors / pharmacology*
  • alpha-Crystallin B Chain / pharmacology
  • alpha-Crystallin B Chain / physiology

Substances

  • Heat-Shock Proteins, Small
  • Peptides
  • Platelet Aggregation Inhibitors
  • alpha-Crystallin B Chain